Which vaccines will RFK end recommendations for?
$1,399,277 Vol.
Dec 31, 2025
Polio
$22,600 Vol.
No
COVID-19
$602,048 Vol.
No
HPV
$316,492 Vol.
No
Influenza
$28,349 Vol.
No
Hepatitis B
$166,216 Vol.
No
Measles Mumps and Rubella
$263,573 Vol.
No
This market will resolve to "Yes" if the CDC has completely ended its recommendation for the listed vaccine, meaning it no longer recommends it for any category of individuals by December 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A reduction in the scope of recommended recipients, or the removal of a recommendation for a specific type of vaccine for the listed disease (e.g. CDC removal of the recommendation for the live oral polio vaccine in 2022) without fully eliminating the recommendation will not be sufficient for a "Yes" resolution.
The resolution source will be official CDC announcements and guidance published on the CDC website (see: https://www.cdc.gov/acip-recs/hcp/vaccine-specific/).This market will resolve to "Yes" if the CDC has completely ended its recommendation for the listed vaccine, meaning it no longer recommends it for any category of individuals by December 31, 2025, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A reduction in the scope of recommended recipients, or the removal of a recommendation for a specific type of vaccine for the listed disease (e.g. CDC removal of the recommendation for the live oral polio vaccine in 2022) without fully eliminating the recommendation will not be sufficient for a "Yes" resolution.
The resolution source will be official CDC announcements and guidance published on the CDC website (see: https://www.cdc.gov/acip-recs/hcp/vaccine-specific/).
A reduction in the scope of recommended recipients, or the removal of a recommendation for a specific type of vaccine for the listed disease (e.g. CDC removal of the recommendation for the live oral polio vaccine in 2022) without fully eliminating the recommendation will not be sufficient for a "Yes" resolution.
The resolution source will be official CDC announcements and guidance published on the CDC website (see: https://www.cdc.gov/acip-recs/hcp/vaccine-specific/).
Created At: Feb 21, 2025, 7:10 PM ET
Volume
$1,399,277End Date
Dec 31, 2025Created At
Feb 21, 2025, 7:10 PM ETResolver
0x6A9D22261...Outcome proposed: No
No dispute
Final outcome: No
Which vaccines will RFK end recommendations for?
$1,399,277 Vol.
Polio
$22,600 Vol.
No
COVID-19
$602,048 Vol.
No
HPV
$316,492 Vol.
No
Influenza
$28,349 Vol.
No
Hepatitis B
$166,216 Vol.
No
Measles Mumps and Rubella
$263,573 Vol.
No
Beware of external links.
Beware of external links.
Frequently Asked Questions
"Which vaccines will RFK end recommendations for?" is a prediction market on Polymarket with 6 possible outcomes where traders buy and sell shares based on what they believe will happen. The current leading outcome is "Polio" at 0%, followed by "COVID-19" at 0%. Prices reflect real-time crowd-sourced probabilities. For example, a share priced at 0¢ implies that the market collectively assigns a 0% chance to that outcome. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.
As of today, "Which vaccines will RFK end recommendations for?" has generated $1.4 million in total trading volume since the market launched on Feb 22, 2025. This level of trading activity reflects strong engagement from the Polymarket community and helps ensure that the current odds are informed by a deep pool of market participants. You can track live price movements and trade on any outcome directly on this page.
To trade on "Which vaccines will RFK end recommendations for?," browse the 6 available outcomes listed on this page. Each outcome displays a current price representing the market's implied probability. To take a position, select the outcome you believe is most likely, choose "Yes" to trade in favor of it or "No" to trade against it, enter your amount, and click "Trade." If your chosen outcome is correct when the market resolves, your "Yes" shares pay out $1 each. If it's incorrect, they pay out $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.
This is a wide-open market. The current leader for "Which vaccines will RFK end recommendations for?" is "Polio" at just 0%, with "COVID-19" close behind at 0%. With no outcome commanding a strong majority, traders see this as highly uncertain, which can present unique trading opportunities. These odds update in real-time, so bookmark this page to watch how the probabilities evolve.
The resolution rules for "Which vaccines will RFK end recommendations for?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.




Beware of external links.
Beware of external links.
Frequently Asked Questions